Global Proteomics Market by Product Type (Reagents, Services, Instruments), By Technology (Spectroscopy, X-Ray Crystallography) By Application (Drug Discovery, Clinical Diagnostic Disease Diagnosis & Others), End- User (Hospitals, Clinical Laboratories) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The Global Proteomics Market size is expected to be worth around USD 103.8 Billion by 2032 from USD 26.8 Billion in 2022, growing at a CAGR of 14.9% during the forecast period from 2022 to 2032.

The study of proteomics extensively is called proteomics. A set of proteins produced biological entity is known as a proteome. The market study report on the global proteomics market deals with proteomics which is the study of proteomes. Proteomics is used to investigate when and where proteins are expressed, the rate at which proteins are degraded, and described, and how proteins are modified.

For example, proteins can belong to a species. At the protein level, proteomic research provides a comprehensive understanding of the processes that underlie both healthy and diseased cellular processes. In contrast to the genome, the proteome, a collection of genes found in every organism, is dynamic and adapts over time and throughout an organism’s life cycle.

The study of when and where proteins are expressed is done with proteomics; steady-state abundance, protein degradation, and production rates; how mutations occur in proteins; movement of proteins among subcellular regions; proteins’ involvement in metabolic pathways; and the interactions between proteins. Proteomics also provides essential information for numerous biological issues, such as proteins being involved in a biological process or which proteins interact with a particular protein of interest, such as the tumor suppressor protein p53.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• The Proteomics Market is expected to reach $103.8 billion by 2032.
  It had a revenue of $26.8 billion in 2022.
• The market is set to grow at a rate of 14.9% annually from 2023 to 2032.
• The reagent and consumables category generates the most revenue.
• Protein microarray technology holds the largest market share.
• Clinical diagnostics is the leading application segment.
• Pharmaceutical companies are a significant end-user.
• North America contributes 45% of the market’s revenue.
• The National Institutes of Health (NIH) invested $37 billion in proteomics research.
• Rising cancer cases drive proteomics market growth.
• Technological advancements, like 2-D electrophoresis protein analyzers, boost the market.
• Collaborations between companies drive research and development.
• Artificial intelligence is reshaping proteomics.
• Drug discovery and emerging technologies are market accelerators.
• Proteomics aids in personalized medicine and COVID-19 research.
• Major players include Illumina, GE Healthcare, Thermo Fisher Scientific, and more.

Type Analysis

The reagents and Consumables segment dominates the market growth of the global proteomics market

The proteomics market is segmented based on types of reagents, services and instruments, and consumables. Among these types, the reagent and consumables segment is the most lucrative in the global proteomics market and accounts for the highest percentage of revenue in the global market. During the forecast period, the section is anticipated to grow the fastest.

The widespread use of reagents and consumables, chemicals, kits, and strips for examining various biological samples in research labs, academic institutions, and other institutions will increase demand for reagents and consumables, thus increasing segmental growth. However, technological advances in advanced instruments like 2 d electrophoresis protein analyzers that improve biological research’s speed and efficiency will support proteomics market growth.

Technology Analysis

Protein microarray accounts for the highest revenue during the forecast period

Based on technological analysis, the market is segmented into spectroscopy, x-ray crystallography, and protein microarray instruments. The protein microarray segment is anticipated to account for the largest proteomics market share during the forecast period.

Based on instrument type. It takes only a limited sample to produce multiple findings. This technology also benefits label-free identification, total direct quantification, and full protein imprinting. Protein fractionation is projected to expand at the highest rate in the future due to the determination and effective isolation of altered proteins in complex structures.

Application Analysis

Clinical diagnostics accounted for the largest revenue share during the forecast period

Based on application, the market is segmented into drug discovery, clinical diagnostic, disease diagnostic, and others. Clinical diagnosis is further segmented into infectious disease, cancer, and neurological disease. The clinical diagnostic segment accounted for the largest share in the forecast period due to an increased understanding of protein expression structure for drug development and disease.

The drug discovery segment is anticipated to grow at the highest CAGR because of the continuous search for proficient ways to deliver enhanced drugs.

End-User Analysis

The hospital’s segment accounted significant market share

The market is segmented into hospitals, pharmaceutical companies, and clinical laboratories based on end-to-user. The pharmaceutical companies segment accounted for a significant market share during the forecast period. The large share of this market can be recognized as the increase in research funding for genomics and proteomics research and the rise in outsourcing of research activities to various pharmaceutical companies

Key Market Segments

Based on Type

• Reagent
• Services
• Instruments
• Consumables

Based on Technology

• Spectroscopy
• X-Ray Crystallography
• Protein Microarray Instruments

Based on Application

• Drug Discovery
• Clinical Diagnostic
• Disease Diagnosis
• Others

Based On End- User

• Hospitals
• Pharmaceutical Companies
• Clinical Laboratories
• Others

Drivers

Rising Drug Prevalence Cancer and Associated Genetic Disorder

Several significant discoveries in life science have been made in the past few days, including completing human genome sequencing. The next major biomedicine milestone was the characterization of human protein, an extremely and relatively new dynamic branch of science focused on evaluating gene expression at the proteome level.

With limited research implemented in proteomics to date, present proteomics is restricted to dealing with numerous issues such as identification, quantification, structure and function, and description of possible interaction, furthermore with increasing research efforts, both technical and Monetary, the field of proteomics is anticipated to incorporate technologies that can be applied to tissue samples to extract important biological information in the form of biomarkers to aid scientist in accepting the dynamic biology of their system of interest like the patient with cancer.

The rise in demand for personalized pharmaceuticals as well as increased research and development in proteomics are further driving the market growth. The rise in research activities in the healthcare industry and the rising need for improved healthcare infrastructure are key factors anticipated to drive the growth of the market.

Restraints

Strict government regulations high cost of medical devices restraint market growth

Strict government regulation, high cost of medical devices, lack of professional researchers, high cost of research and development, and lack of awareness concerning the application of proteomics in developed nations are likely to restrain the global proteomics market growth to a lesser extent.

Moreover, factors such as sequestration occurring in the US and reduced funds for proteomics investigation, a huge disconnect between biomarker authorization and biomarker discovery authorization by regulatory authorities, expensive instruments and their maintenance, and reduction in free trade are anticipated to trial the market during the forecast period.

Opportunity

Increasing Prominence of Nanoproteomics

The field of nanotechnology has been related to several proteomics applications like Nanostructured surfaces for protein separation also analytical detection of biomarker proteins by expanding array techniques.

The technique is developing as a complementary constituent to transform proteomics through different nanotechnology applications and polymeric nanostructures. This has directed the occurrence of Nano proteomic science involving the application of proteomics techniques assisted by nanotechnology.

Trends

A Leading Trend Gaining Pace of Proteomics Market

A prominent trend gaining pace proteomics market is artificial intelligence in proteomics. Artificial intelligence applications in proteomics are already rewriting the drug discovery landscape. Considering how and why specific protein interact is critical for developing new drugs, processing cell biology, and determining how drugs may have therapeutic and adverse effects.

More trends in the market are augmenting the growth of the proteomic market during the forecast period, including the surge in drug discovery, developing technologies, the growing prominence of Nano proteomics, and new applications based on proteomic technology advancement.

Regional Analysis

North America predicted the Largest Share of the Global Proteomics Market

Geographic regions such as North America, Europe, Asia-Pacific, South America, and the Middle East and Africa are observed in the global proteomics market. The industry was dominated by North America, which generated the highest revenue of 45% during the forecast period.

This is due to increased investments in structure-based drug design, expansion of omics research, the need for high-quality data reproducibility tools, and a focus on creating custom treatments. The market’s development is also aided by major regional businesses’ partnerships and collaborations.

For instance, Symphogen and Thermo Fisher Scientific Inc. worked together to create authorized platform processes for the simplified characterization and quality monitoring of complex therapeutic proteins.

Proteomics-based project outsourcing, public and private funding for proteomics research and development, favorable government regulations, rising target disease prevalence with an aging population, and rising proteomics adoption all contribute to the Asia-Pacific region’s fastest CAGR between 2022 and 2038.

For instance, in November, the Indian Government’s Department of Biotechnology awarded the University of Hyderabad a million for research on the tomato proteome. The Asian-Pacific market is driven by government initiatives to support proteomics research.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

The Key Players continuously invest in strategic initiatives like new product launches, introducing their products to emerging markets, and maintaining competitive advantage. To strengthen their position in the market, major players are employing various strategies, such as geographical expansion, strategic collaborations, partnerships made possible by mergers and acquisitions, and so on. For instance, Seer, Inc. announced the Broad Commercial Release of the Proteograph Product Suite and the debut of the Centers of Excellence program in January 2022.

The Proteograph Product Suite provides unrivaled, impartial access to the proteome. The novel product that results from the method’s use of one-of-a-kind nanoparticles paves the way for rapid, thorough, and impartial scale proteomics. The following are some of the major players in the global proteomics market Illumina Inc., Thermo Fisher Scientific Inc., Promega Corporation, Bruker Corporation, and Bio-Rad Laboratories Inc.

Market Key Players

• Illumina, Inc.
• GE Healthcare
• Thermo Fisher Scientific Inc.
• Bruker Corporation
• Promega Corporation
• Agilent Technologies Inc.
• Merck KGaA.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• F Hoffmann-La Roche Ltd.
• Waters Corporation
• Luminex Corporation
• Caprion Proteomics Inc.
• PerkinElmer, Inc.

Recent Developments

• August 2022- Bruker Corporation launched the new nano Elute 2 nano-LC and MetaboScape and TASQ software supporting fluxomics, and the latest advances in PaSER intelligent acquisition to enhance research in protein-protein interaction and metaproteomics application.
• March 2021- Thermo Fischer Scientific, the world’s prominent in servicing science, cooperated with Protein Metrics a developer of world-class software tools for protein characterization, have entered into non-exclusive co-marketing acknowledgment to offer advanced mass spectrometry data processing and analysis abilities to drive innovation across the biopharmaceutical and proteomics application, from investigation and development quality control.

Report Scope